Versant Ventures

AllRock Bio is a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary diseases, particularly pulmonary arterial hypertension and interstitial lung diseases.

Granite Bio is a biotechnology company developing first-in-class antibodies targeting the root causes of inflammatory, autoimmune, and fibrotic diseases.

Crinetics is a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors.

Monte Rosa Therapeutics is focused on developing molecular glue degraders (MGDs) that target undruggable proteins for therapeutic purposes, particularly in immunology and inflammation.

Hotspur Technologies offers IT solutions and services including web development, app development, and technical support. They provide cutting-edge technology services tailored to meet the unique needs of businesses across various industries.

SixPeaks Bio AG is developing innovative therapies for healthy weight loss and metabolic fitness, focusing on preserving skeletal muscle mass while utilizing GLP-1 receptor agonists.

Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Seed and early-stage investor that creates and invests in biotech startup companies, emphasizing company creation.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.